PDF(Pubmed)
Abstract：
Inflammatory bowel diseases represent a complex array of diseases of incompletely known etiology that led to gastrointestinal tract chronic inflammation. In inflammatory bowel disease, a promising method of treatment is represented by fecal microbiota transplantation (FMT), FMT has shown its increasing effectiveness and safety in recent years for recurrent CDI; moreover, it showed real clinical benefits in treating SARS-CoV-2 and CDI co-infection. Crohn\'s disease and ulcerative colitis are characterized by immune dysregulation, resulting in digestive tract damage caused by immune responses. Most current therapeutic strategies are associated with high costs and many adverse effects by directly targeting the immune response, so modifying the microbial environment by FMT offers an alternative approach that could indirectly influence the host\'s immune system in a safe way. Studies outline the endoscopic and clinical improvements in UC and CD in FMT patients versus control groups. This review outlines the multiple benefits of FMT in the case of IBD by improving patients unbalanced gut, therefore improving endoscopic and clinical symptomatology. We aim to emphasize the clinical importance and benefits of FMT in order to prevent flares or complications of IBD and to highlight that further validation is needed for establishing a clinical protocol for FMT in IBD.
摘要：
炎症性肠病代表一系列复杂的疾病，其病因尚不完全清楚，导致胃肠道慢性炎症。在炎症性肠病中，一种有前途的治疗方法是粪便微生物移植（FMT），近年来，FMT对复发性CDI的有效性和安全性越来越高；此外，它在治疗SARS-CoV-2和CDI合并感染方面显示出真正的临床益处。克罗恩病和溃疡性结肠炎的特点是免疫失调，导致消化道损伤引起的免疫反应。大多数目前的治疗策略与高成本和许多副作用有关，直接针对免疫反应。因此，通过FMT改变微生物环境提供了一种替代方法，可以以安全的方式间接影响宿主的免疫系统。研究概述了FMT患者与对照组的UC和CD的内镜和临床改善。这篇综述概述了FMT在IBD病例中通过改善患者不平衡的肠道，因此改善内窥镜和临床症状学。我们旨在强调FMT的临床重要性和益处，以预防IBD的耀斑或并发症，并强调需要进一步验证以建立IBD中FMT的临床方案。
